Thrombolytic therapy in dogs and cats

Journal of Veterinary Emergency and Critical Care

Volumn 11, Issue 2, 2001, Pages 111-121

  Thompson, Mary F ^a   Scott Moncrieff, J Catharine ^a   Hogan, Daniel F ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Fibrinolysis; Hypercoagulable; Thromboembolism; Thrombolysis; Thrombosis

Indexed keywords

EID: 0005298199     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2001.tb00077.x     Document Type: Article

References (90)

1. Marder VJ, Sherry S. Thrombolytic therapy: Current status (First of Two Parts). N Engl J Med 1988;318(3)1512–1520.
2. Zivin JA. Thrombolytic stroke therapy; past, present and future, Neurology 1999;53:14–9.
3. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival. J Am Coll Cardiol 1987;7:717–728.
4. Schroder R, Neuhaus KL, Leizorovica A, et al. A prospective placebo-controlled double-blind multicenter trial of intravenous streptokinase in acute myocardial infarction (ISAM): Long term mortality and morbidity. J Am Coll Cardiol 1987;9:197–203.
5. Wilcox RB, Olsson CJ, Skene AM et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988;2:525–530.
6. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:545–549.
7. Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 Dogs: 1985-1995. J Vet Intern Med 1990;13:338–345.
8. Norris CR, Griffey SM, Samii VE. Pulmonary thromboembolism in cats: 29 cases (1987-1997). J Am Vet Med Assoc 1999;215(11):1650–1654.
9. Welles EG. Antithrombotic and fibrinolytic factors- A review. Vet Clin North Am Sm Anim Pract 1996; 26(5): 1111–1125.
10. Bick RL. Hypercoagulability and thrombosis. Vet Clin North Am Sm Anim Pract 1994;78(3):635–665.
11. Takada Y, Takada A. The Mechanisms of the Activation of Plasminogen by Streptokinase and Urokinase. In: Liu CY, Chien S, Fibrinogen, Thrombosis, Coagulation and Fibrinolysis editors. New York : Plenum Press; 1990. P. 223–234.
12. Loscalzo J, Braunwald E. Tissue Plasminogen activator. N Engl J Med 1988;319(14):925–931.
13. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988;77(3):670–677.
14. Braunwald E. Heart Disease: a textbook of cardiovascular medicine, 5th ed. Philadelphia, PA : WB Saunders; 1997; 1814–1816.
15. Gulba DC, Bode C, Runge MS, et al. Thrombolytic agents an overview. Ann Hematol 1996;73(Supp 1):S9–S27.
16. Anonick PK, Wolf BB, Gonias SL. Regulation of plasmin, miniplasmin, and streptokinase-plasminogen complex by alpha-2-antiplasmin, alpha-2 macroglobulin, and antithrombin III in the presence of heparin. Thromb Res 1990;59(3):449–462.
17. Collen D, de Cook F, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost 1984;52:24–26.
18. Guyton AC, Hall JE. Hemostasis and blood coagulation. In: AC Guyton, JE Hall, editors. Textbook of Medical Physiology. Philadelphia : WB Saunders; 1996. p.463–473.
19. Comeroto AJ, Cohen GS. Thrombolytic therapy in peripheral arterial occlusive disease: Mechanisms of action and drugs available. Can J Surg 1992; (Supp).
20. Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11:1–11.
21. Neuhaus KL, Tebbe U, Gottwick M, et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German activator urokinase study (GAUS). J Am Coll Cardiol 1998;12:581–587.
22. Goldhaber SZ, Kessler HM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1998;2:293–8.
23. Goldhaber SZ, Kessler CM, Heit JA, et al, t-PA vs. uroki nase in acute pulmonary embolism: a randomized controlled trial. Circulation 1991;84(Supp II):357.
24. Becker RC. Recombinant t-PA and platelet activity. Cleve Clin J Med 1990;57:537–541.
25. Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990;97(4):161S–67S.
26. Eisenberg PR, Sherman LA, Tiefenbrunn AJ, et al. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Hemostat 1987;57:35–40.
27. Goldhaber, SZ. Treatment of pulmonary thromboembolism. Intern Med 1999;38:620–625.
28. Goldhaber SZ, Agnelli G, Levine MN. Reduced bolus dose alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized tiral. Chest 1994; 106:718–724.
29. Goldhaber, Feldstein MI, Sors H. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism: an overview. Chest 1994;106:725–726.
30. Grines CL. Thrombolytic, antiplatelet, and antithrombotic Agents. Am J Cardiol 1992;70:181–261.
31. White HD. Comparative safety of thrombolytic agents. Am J Cardiol 1992;69:12A–20A.
32. Buckenham TM, George CD, Chester JF, et al. Accelerated thrombolysis using pulsed intra-thrombus recombinant human tissue type plasminogen activator (rt-PA). Eur J Vasc Surg 1992;6:237–240.
33. Shiffman F, Ducas J, Hollet P, et al. Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator- efficacy of dosing regimes. Circulation 1998;78(1):214–220.
34. Lijnen HR, De Reed K, Demarsin E, et al. Biological and thrombolytic properties of proenzyme and active forms of human urokinase- IV. Variability in fibrinolytic responses of plasma of several mammalian species. Thromb Haemost 1984;52:31–33.
35. Zamarron C, Lijnen HR, Van Hef B, et al. Biological and thrombolytic properties of proenzyme and active forms of human urokinase obtained from human urine or by recombinant DNA technology. Thromb Haemost 52:19–23, 1984.
36. Badylak SF, Voytik S, Klabunde RE, et al. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Thromb Res 1988;52:295–312.
37. Kohler M, Sen S, Hermes R, et al. Pharmacokinetics of single-chain urokinase-type plasminogen activator (scuPA) in patients with acute myocardial infarction. Ann Hematol 1991;62 Supp A:A7(Abstract).
38. Matsuo O, Collen D, Verstrate M. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). Thromb Res 1981;24: 347–358.
39. Smith RAG, Dupe RJ, English PD, et al. Acylated enzymes as thrombolytic agents in a rabbit model of venous thrombosis. Thromb Haemost 1982;47:269–274.
40. Dupe RJ, Green J, Smith RAG. Acylated derivatives of streptokinase plasminogen activator complex as thrombolytic agents in a dog model of aged venous thrombosis. Thromb Haemost 1985;53:56–59.
41. Brochier ML, Quillet L, Kulbertus H, et al. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Primary data from a randomized multicenter study. Drugs 1987;33(Supp 3):40–145.
42. Brugemann J, van der Meer J, Takens BH, et al. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction. Br Heart J 1990;64:355–358.
43. ISIS-3 (Third international Study of Infarct Survival) Collaborative Group ISIS 3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute infarction. Lancet 1993; 339:753–770.
44. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism- results of a multicenter registry. Circulation 1997;96:882–888.
45. Goldhaber SZ, Haire WD, Feldstein M, et al. Alteplase versus heparin in acute pulmonary emoblism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507–11.
46. Goldhaber SZ, Vaughan DE, Markis JE, et al. Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986;2:886–9.
47. Jerjes-Sanchez C, Ramirez, -Rivera A, Garcia M de L, et al. Streptokinase and heparin versus heparin alone in massive pulmonary emoblism: a randomized controlled trial. J Thromb Thrombolysis 1995;2:227–229.
48. Miller GAH, Sutton GC, Kerr IH. Comparison of streptolinase and heparin in the treatment of isolated acute massive pulmonary embolism. Br Med J 1971;2:681–684.
49. Konstantinides S, Tiede N, Geibel A. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1988;82:966–970.
50. Sharma GVRK, Burleson VA, Sasahara A. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary-caplillary blood volume in patients with pulmonary embolism. N Engl J Med 1980;303:842–845.
51. Marini C, Di Ricco G, Rossi G, et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988;54:162–173.
52. Pioped Investigators Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study by the PIOPED investigators. Chest 1990;97:528–533.
53. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus regimen of recombinant tissue plasminogen activator in patients with acute pulmonary emoblism. Chest 1990;98:1473–1479.
54. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary emoblism: Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol 1992;20(3):520–526.
55. Davies MJ. Pathology of arterial thrombosis. Br Med Bull 1994;50(4):789–802.
56. Amery A, Deloog W, Vermylen et al. Outcome of recent thromboembolic occlusions of limb arteries with streptokinase. Br Med J 1970;4: 639–644.
57. Verstraete M, Vermylen J and Donati MB. The effect of streptokinase infusion on chronic arterial occlusions and stenoses. Ann Int Med 1971;74:377–382.
58. Becker RC. Management of venous and arterial disorders. In: Becker RC, editor. Fibrinolytic and Antithrombotic Therapy. New York : University Press; 2000. p. 565–581.
59. Killingsworth CR, Eyster GE, Adams T et al. Streptokinase treatment of cats with experimentally induced aortic thrombosis. Am J Vet Res 1986;47:1351–1359.
60. Ramsey CC, Riepe RD, Macintire DK, et al. Streptokinase: A practical clot buster? In: Proceedings, Fifth International Vet Emerg and Crit Care Symposium. San Antonio, TX; 1996; 225–228.
61. Moore KE, Morris N, Dhupa N, et al. Retrospective Study of Streptokinase Administration in 46 cats with Arterial Thromboembolism. J Vet Emerg Crit Care 2000; 10(4):245–257.
62. Schaub R, Gates K, Roberts R. Effect of aspirin on collateral blood flow after experimental thrombosis of the feline aorta. Am J Vet Res 1982;43:1647–1650.
63. Ramsey CC, Burney DP, Macintire DK, et al. Use of Streptokinase in four dogs with thrombosis. J Am Vet Med Assoc 1996;209(4):780–785.
64. Pion P, Kittleson M. Therapy for feline aortic thromboembolism. In: Kirk R, editor. Current Veterinary Therapy X. Philadelphia : WB Saunders; 1989, 295–302.
65. Clare A, Kraje BJ. Use of recombinant tissue-plsmingoen activator for aortic thrombolysis in a hypoproteinemic dog. J Am Vet Med Assoc 1998;212(4):539–543.
66. Boswood A, Lamb CR, White RN. Aortic and illiac thrombosis in six dogs. J Small Anim Pract 2000;41:109–114.
67. Arcaso SM and Kreit JW. Thrombolytic therapy of pulmonary embolism. Chest 1999;115(6):1695–1707.
68. Patel SC and Mody A. Cerebral hemorrhagic complications of thrombolytic therapy. Prog Cardiovas Dis 1999; 42(3):217–233.
69. Hudson KF. A phenomenon of paradox: myocardial reperfusion injury. Heart Lung 1994;23(5):394–396.
70. Pion P. Felin Aortic Thromboembolism and the potential utility of thrombolytic therapy with tissue plasminogen activator. Vet Clin North Am Sm Anim Pract 1988; 18(1):79–87.
71. Shafer KE, Santoro SA, Sobel BE, et al. Monitoring activity of fibrinolytic agents. Am J Med 1984;76:879–886.
72. Warren RJ. The management of acute myocardial infarction: Does thrombolysis have a place Aust Family Physician 2000;29(5):436–439.
73. Streptokinase package insert.
74. Calvert CA. Selected Complications and Sequelae of Canine Heartworm Disease. Sem Vet Med Surg (Small Anim) 1987;2(1):56–63.
75. Greco DS, Green RA. Coagulation abnormalities associated with thrombosis in a dog with nephrotic syndrome. Compend Contin Educ Pract Vet 1987;9(6):653–658.
76. Klein MK, Dow SW, Rosychuk RA. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in Dogs: Ten Cases (1982-1987). J Am Vet Med Assoc 1989;195(2): 246–250.
77. LaRue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 Cases (1986-1987). J Am Vet Med Assoc 1990; 197(10): 1368–1372.
78. Fluckiger MA, Gomez JA. Radiographic findings in dogs with spontaneous pulmonary thrombosis or embolism. Vet Radiology 1994;25(3):124–131.
79. Van Winkle TJ, Hackner SG, Liu SM. Clinical and pathological features of aortic thromboembolism in 36 Dogs. J Vet Emerg and Crit Care 1993;3(1):13–21.
80. Bunch SE, Metcalf MR, Crane SW, et al. Idiopathic pleural effusion and pulmonary thromboembolism in a dog with autoimmune hemolytic anemia. J Am Vet Med Assoc 1989;195(12):1748–1753.
81. Burns MG, Kelly AB, Hornoff WJ, et al. Pulmonary artery thrombosis in three dogs with hyperadrenocorticism. J Am Vet Med Assoc 1981;178: 388–393.
82. King RR, Mauderly JL, Hahn FF, et al. Pulmonary function studies in a dog with pulmonary thromboembolism associated with Cushings Disease. J Am Anim Hosp Assoc 1985;21:555–562.
83. Carter AJ, Van Heerden J. Aortic thrombosis in a dog with glomerulonephritis. J S Afr Vet Assoc 1994;65(4):189–192.
84. Slauson DO, Gribble DH. Thrombosis complicating renal amyloidosis in dogs. Vet Pathol 1971;8:352–363.
85. Dibartolo SP, Meuten DJ. Renal amyloidosis in two dogs presented for thromboembolic phenomena. J Am Anim Hosp Assoc 1980; 16:129–135.
86. Hargis AM, Stephens LC, Benjamin SA, et al. Relationship of hypothroidism to diabetes mellitus, renal amyloidosis, and thrombosis is purebred beagles. Am J Vet Res 1981;42: 1077–1081.
87. Laste NJ and Harpster NK. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993. J Am Vet Med Assoc 1995;31:492–500.
88. Isacson S. Effect of prednisone on the coagulation and fibrinolytic systems. Scand J Haematol 1970;7:212–6.
89. Van Winkle TJ and Bruce E. Thrombosis of the portal vein in eleven Dogs. Vet Pathol 1993;30:28–35.
90. Fox, PR. Feline Thromboembolism associated with cardiomyiopathy. In: Proceedings of the Fifth Annual Vet Med Forum ACTVIM. San Diego, CA; 1987; 714–718.